# Study of Subcutaneously Administered Peginesatide in Anemic Cancer Patients Receiving Chemotherapy

> **NCT00272662** · PHASE2 · COMPLETED · sponsor: **Affymax** · enrollment: 60 (actual)

## Conditions studied

- Chemotherapy Induced Anemia
- Cancer

## Interventions

- **DRUG:** peginesatide

## Key facts

- **NCT ID:** NCT00272662
- **Lead sponsor:** Affymax
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-01
- **Primary completion:** 2007-06
- **Final completion:** 2007-06
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2012-12-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00272662

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00272662, "Study of Subcutaneously Administered Peginesatide in Anemic Cancer Patients Receiving Chemotherapy". Retrieved via AI Analytics 2026-09-08 from https://api.ai-analytics.org/clinical/NCT00272662. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*